Pulmonary Fibrosis Foundation
“Patients, caregivers, and physicians discuss the disease and the role the Pulmonary Fibrosis Foundation has played in the past years.” Learn more about Pulmonary Fibrosis Foundation:Â http://bit.ly/1MkiSzf …
Pulmonary Fibrosis Foundation
#TBT – Remembering Evel Knievel
Evel Knievel was an American daredevil, entertainer, and international icon. He attempted more than 75 ramp-to-ramp motorcycle jumps between 1965 and 1980, and in 1974, a canyon jump across Snake River Canyon (which failed) in a team-powered rocket. During his career, he suffered more than 433 bone fractures, which gave…
Potential Therapy for Severe Lung Disease Advances at aTyr Pharma
aTyr Pharma Inc., a biotherapeutics company that discovers and develops medicines through its Physiocrine platform for the treatment of rare diseases, has announced the selection of a new Investigational New Drug (IND) candidate, an iMod.Fc molecule. The selected therapeutic molecule aims to aid in the management of severe fibrotic…
OFEV Efficacy Supported in a New Study
Boehringer Ingelheim Pharmaceuticals recently presented results of the Phase III INPULSIS trials investigating the efficacy of OFEV ® (nintedanib) in patients with idiopathic pulmonary fibrosis (IPF) at the American College of Chest Physicians Annual Meeting (CHEST 2015). The Phase III INPULSIS trials were randomized, double-blind studies designed to assess both…
Interstitial Lung Disease Remains Major Diagnostic Challenge
Veracyte, Inc.recently presented four abstracts  on current diagnostic challenges related to interstitial lung disease (ILD) and the potential for improved diagnostic procedures using novel genomic-based strategies. The abstracts were given at the Pulmonary Fibrosis Foundation’s PFF Summit 2015: From Bench to Bedside at the JW Marriott Hotel in Washington, D.C., in…
Approved Pulmonary Fibrosis Therapies
Learn more about Approved IPF Therapies Ofev and Esbriet. Read more about Pulmonary Fibrosis: http://bit.ly/1lfMsiZ…
Last Week’s Most Read Posts On Pulmonary Fibrosis
1. Pulmonary Fibrosis Foundation Sets Scientific Record at Upcoming Summit 2. Lung Stem Cell Spheroids Could Offer Cheap, Rapid Pulmonary Fibrosis Therapy 3. Genentech to Help Support Pulmonary Fibrosis Foundation Programs…
Boehringer Ingelheim’s OFEV (Nintedanib) IPF Therapy Reinforces Efficacy and Safety Profile in New Studies
Boehringer Ingelheim recently announced new positive data on the company’s FDA-approved therapy OFEV® (nintedanib) for the treatment of idiopathic pulmonary fibrosis (IPF). The results were presented at the Pulmonary Fibrosis Foundation’s PFF Summit 2015 in Washington, D.C. OFEV is a tyrosine-kinase inhibitor (TKI) that targets growth factors, such as the vascular endothelial…
Pulmonary Fibrosis & Hope: A Lung Transplant Documentary
“Dot Delarosa always had a challenging life, but things got worse when she found out that she had Pulmonary Fibrosis. She needed a lung transplant immediately, or she would die. This is her story.” Learn more Pulmonary Fibrosis:Â http://bit.ly/1lfMsiZ…
Pulmonary Fibrosis Patients With PH Get Techno Boost in phaware365 App
The nonprofit phaware global association (phaware), an organization focused on raising awareness of pulmonary hypertension, has developed a new mobile app (phaware365) to help achieve its goal globally through an innovative and engaging strategy. Pulmonary hypertension (PH) is a life-threatening cardiopulmonary disorder characterized by an abnormally high blood pressure in the…
